Role of Calcium Channels in Vascular Function

May 28, 2021 updated by: Stefan Mortensen, University of Southern Denmark

Role of T-type Calcium Channels in Vascular Function

The purpose of this study is to examine the role of T-type calcium channels in endothelial dysfunction observed with ageing.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

12

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Denmark
      • Copenhagen, Denmark, 2100
        • Centre for Phsical Activity Research
      • Odense, Denmark, 5000
        • Cardiovascular and Renal Research

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years to 66 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • age 20 - 30 and 60-70
  • BMI < 30

Exclusion Criteria:

  • Hypertension (>150/90 mmHg)
  • Smoking
  • Physical activity >2 hours/week
  • Known chronic diseases
  • Pregnancy or birth within 3 month
  • Alcohol misuse

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: L + T-type
8 weeks treatment with efonidipine (1 week 1x20mg, 7 weeks 2x20mg)
Drug: Efonidipine
8 weeks treatment with either efonidipine
Other Names:
  • Landel (efonidipine)
Active Comparator: L-Type
8 weeks treatment with nifedipine (1 week 1x20mg, 7 weeks 2x20mg)
Drug: Nifedipine
8 weeks treatment with either nifedipine
Other Names:
  • Adalat (nifedipine)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Vascular function
Time Frame: 8 weeks
Hemodynamic response to femoral arterially infused vasoactive substances
8 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Southern Denmark

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 1, 2017

Primary Completion (Actual)

May 25, 2021

Study Completion (Actual)

May 25, 2021

Study Registration Dates

First Submitted

August 26, 2016

First Submitted That Met QC Criteria

August 30, 2016

First Posted (Estimate)

August 31, 2016

Study Record Updates

Last Update Posted (Actual)

June 1, 2021

Last Update Submitted That Met QC Criteria

May 28, 2021

Last Verified

May 1, 2021

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 47880

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Endothelium, Vascular

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Norway

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe